Pre-Clinical Toxicity: Avoiding Common Mistakes in Early Development
Add bookmark
Pre-Clinical Toxicity: Avoiding Common Mistakes in Early Development
Add bookmarkDr. Mitchell Friedman, Director of Toxicology at Takeda Pharmaceuticals, discusses pre-clinical toxicity and avoiding common mistakes in early development so as to secure patient safety and better ROI.
[inlinead]
Tags:
Mitchell Friedman
toxicology
pre-clinical toxicity
genotoxicity testing
carcinogenicity testing
